Dr. Daniel Kavanagh | Senior Scientific Advisor, Gene Therapy

Daniel Kavanagh is Senior Scientific Advisor, Gene Therapy at WIRB-Copernicus Group. Prior to joining WCG, he was Assistant Professor of Medicine at Harvard Medical School, Assistant Immunologist at the Massachusetts General Hospital, and a Principal Investigator studying infectious diseases at the Ragon Institute of MGH, MIT, and Harvard. Dr. Kavanagh holds a PhD in Molecular Microbiology and Immunology from the Oregon Health and Science University, and did postdoctoral training at Harvard Medical School, Boston MA, and the Rockefeller University, New York, NY. Dr. Kavanagh also holds the RAC credential through the Regulatory Affairs Professionals Society.

  • NIH Launches NExTRAC to Advise on Emerging Biotechnologies

    NIH Launches NExTRAC to Advise on Emerging Biotechnologies

    Read Post
  • Amendments to the NIH Guidelines: Effects on Human Gene Transfer Research

    Amendments to the NIH Guidelines: Effects on Human Gene Transfer Research

    On April 25th, NIH Director Francis Collins announced the release of the amended NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. The most important take-home...

    Read Post
  • Germline Modification for HIV Prevention is Unjustified

    Germline Modification for HIV Prevention is Unjustified

    Daniel Kavanagh, PhD, responds to recent news of germline editing of human embryos in China.

    Read Post
  • Changes to Human Gene Transfer Oversight at NIH

    Changes to Human Gene Transfer Oversight at NIH

    Insights on recent NIH changes to oversight of Human Gene Transfer (HGT) research under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.

    Read Post
  • Gene Therapy: New Draft Guidance Will Impact Clinical Trial Designs

    Gene Therapy: New Draft Guidance Will Impact Clinical Trial Designs

    Read Post
  • loading
    Loading More...